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 2
ABSTRACT 1 
Background: The stereospecific structures of the triacylglycerol molecules in human milk 2 
differ from that of cow’s milk and vegetable oils, which are the fat sources used in infant 3 
formula. In human milk, palmitic acid (16:0) is predominantly esterified in the sn2-position, 4 
whereas vegetable oils or cow’s milk fat contain most of their 16:0 in the outer positions of 5 
the triacylglycerol molecules. Furthermore, human milk contains long-chain polyunsaturated 6 
fatty acids (LCPUFA), which are not present in either cow’s milk or vegetable oils.  7 
Methods: By standard lipid analysis procedures we examined the triacylglycerol structures 8 
and fatty acid profiles of fats from 28 infant formulas or formulas for special indications 9 
available on the Danish market 1999-2003.   10 
Results: The total fatty acid compositions of the formulas showed a 16:0 content almost 11 
similar to human milk, whereas the content in the sn2-position was considerably lower. The 12 
content of oleic acid was found to be equal to or higher than in human milk in 21 out of 28 13 
formulas; whereas the content in the sn2-position was higher in all but one formula. Most 14 
formulas had linoleic acid levels considerably above that of human milk. LCPUFA 15 
(arachidonic acid and docosahexaenoic acid) were present in all preterm formulas, but only in 16 
three of the term formulas. 17 
Conclusion: We found that most of the examined infant formulas, both preterm and term as 18 
well as special formulas, had stereospecific structures and fatty acid profiles that differed 19 
considerably from that of human milk.  20 
 21 
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During the last decades there has been increasing interest in the fatty acid composition of 2 
infant formulas (1,2). The interest has focused on the content of polyunsaturated fatty acids 3 
(PUFA), especially the balance between n-3 and n-6 PUFA and the possible need to add the 4 
long-chain PUFA (LCPUFA), docosahexaenoic acid (22:6n-3, DHA) and arachidonic acid 5 
(20:4n-6, ARA). Recently, the importance of the stereospecific triacylglycerol structures has 6 
been demonstrated (3,4). The target has been to produce an infant formula with a fat content, 7 
composition and structure close to that found in human milk. Using a blend of different fats, 8 
mainly vegetable oils, it has been possible to match the overall fatty acid composition of 9 
human milk, but not the triacylglycerol structure.  10 
 Fat absorption is higher from human milk than from infant formula, despite the 11 
similarities between the fatty acid profiles (5). This may partly be explained by the unique 12 
triacylglycerol structure of human milk. Palmitic acid (16:0) is abundant in human milk and 13 
is an important source of energy. Most of the 16:0 in human milk is located in the sn2-14 
position of the triacylglycerol molecules (6), in contrast to cow’s milk and vegetable oils 15 
which have 40 % (7) and 5-20 %, respectively, of the 16:0 in the sn2-position (8). Therefore, 16 
hydrolysis of human milk fat result in 16:0 mainly as sn2-monoacylglycerol, which are well 17 
absorbed (7,9). In contrast, after hydrolysis 16:0 from vegetable oils will be present as free 18 
fatty acids, which tend to bind calcium and form insoluble calcium-soaps in the intestine that 19 
may cause constipation  20 
LCPUFA are present in human milk but have not until now been added to the 21 
majority of standard infant formulas avialable in the Danish market. DHA is important for 22 
development of the nervous system (2) and ARA is the precursor of eicosanoids (10), which 23 
are local mediators involved in, for example, the regulation of the immune function and 24 
platelet aggregation. It is presently recommended that the content of the precursors for these 25 
 4
LCPUFA, linoleic acid (18:2n-6, LA) and α-linolenic acid (18:3n-3, LNA), are 500-1200 1 
mg/100 kcal and above 50 mg/100 kcal, respectively, to the infant formulas without 2 
LCPUFA and that the ratio of LA to LNA should be between 5 and 15 (11). It is generally 3 
agreed that LCPUFA should be added to formulas for preterm infants, whereas no agreement 4 
has been reached on whether to add LCPUFA to formulas for term infants (11,12,13).  5 
The aim of this study was to describe the fatty acid compositions and the 6 
stereospecific triacylglycerol structures of a selection of formulas in the market in Denmark, 7 
to compare these with human milk, when appropriate, and to discuss some of the 8 
consequences of these issues. Our focus was on the content and position in the 9 
triacylglycerols of 16:0, oleic acid (18:1n-9), LA, LNA, DHA and ARA. Furthermore, we 10 
studied structure and profile differences of the fat from formulas with different applications 11 
(for premature, term infants or infants with various disorders), with special focus on the 12 
presence of medium-chain fatty acids (MCFA, 8:0 and 10:0). 13 
 14 
MATERIALS AND METHODS 15 
Twenty-eight different formulas were analyzed. Five of the formulas were for premature 16 
infants; eight for term newborn infants (term infant formulas), four were follow-on formulas 17 
for infants >4 mo of age, and 11 were special formulas for infants and young children with 18 
different disorders (Table 1). The fatty acid profiles and structures were compared to values 19 
from different types of human milk. We analysed a pooled sample of human milk derived 20 
from mothers delivering prematurely before the gestational age of 34 weeks. The mothers 21 
emptied both breasts with the help of an electrical pump and each mother collected the milk 22 
in a 24 hour pool. The milk was collected between the second and fourth week after delivery. 23 
Furthermore, we included in Table 3 sets of values from the literature (6,9,14). We also 24 
 5
analysed cow’s milk (standard full fat pasteurized cow’s milk bought during the month of 1 
February).  2 
The formulas were purchased and analyzed between 1999-2003. Seven of the 3 
formulas were purchased and analyzed both in 1999 and in 2003 (Allomin-1, Allomin-2, 4 
soured Allomin, Baby Milk, Enfalac, Nutramigen and NAN H.A). These analyses gave 5 
similar results with respect to profile and structure for all except one of the formulas. In 2003 6 
Enfalac had increased proportions of 18:1n-9, ARA and DHA and decreased proportions of 7 
lauric acid (12:0) and LA compared to that in the 1999 formula. This paper presents the 8 
results of the most recent analyses.  9 
 10 
Formula fat analysis 11 
Powdered formulas were dissolved in water (250 mg formula/ml water), whereas liquid 12 
formulas, human milk and cow’s milk were extracted from their origin. The fats were 13 
extracted by the Folch procedure (15) and fatty acids were dissolved in heptane. Fatty acid 14 
methyl esters (FAME) were prepared from total lipids through transesterification catalysed 15 
by KOH in methanol (16). The FAME were analysed by gas-liquid chromatography using a 16 
Hewlett-Packard 5890 series II Chromatograph with flame-ionisation detection (Hewlett-17 
Packard GmbH, Waldbronn, Germany), and a fused silica capillary column (SP-2380, 60 m, 18 
ID 0.25 mm, Supelco, Bellefonte, PA). Helium was used as carrier gas. A split ratio of 1:11 19 
was applied in the injector. The column flow was constant at 1.2 mL/min. Initial oven 20 
temperature was 70 oC for 0.5 min and temperature programming was as follows: 15 oC/min 21 
to 160 oC, 1.5 oC/min to 200 oC, which was maintained for 15 min followed by a rate of 30 22 
oC/min to 225 oC, which was then maintained for 5 min. FAME peaks in the chromatogram 23 
(from octanoic acid (8:0) to DHA (from 4:0 for cow´s milk)) were identified from external 24 
 6
standards (Nu-Chek-Prep, Inc. Minnisota, USA). The chromatogram areas of FAME with 1 
fewer than 12 carbons were corrected by response factors. 2 
Regiospecific analyses of the formula fats were performed by degradation of the 3 
triacylglycerol molecules with allylmagnesium bromide as Grignard reagent (17). The sn2-4 
monoacylglycerol fraction was isolated by thin-layer chromatography on boric acid-5 
impregnated thin-layer chromatography-plates developed twice (2*60 min) in 6 
chloroform:acetone (90:10 v/v), methylated, and analysed by gas-liquid chromatography. The 7 
fatty acid profiles of triacylglycerol and the sn2-position (Tables 2-4) are given as the 8 
distribution in wt% of all fatty acids (set to 100 %). The relative proportion of specific fatty 9 
acids in the sn2-position of the triacylglycerol molecule was calculated as: (M/T*3)*100, 10 
where M is the percentage of the fatty acid in the sn2-position and T is the percentage of the 11 
fatty acid in triacylglycerol (18). Data for the fatty acid profiles represent the mean of two 12 
determinations, whereas the analyses of the sn2-position represent the mean of three or four 13 
determinations. The standard error of the mean (SEM) was <3 % for fatty acids in 14 
triacyglycerol and <5 % for the sn2-monoacylglycerols. 15 
 16 
RESULTS 17 
The fatty acid profiles and the sn2-fatty acids of the analysed infant formulas were 18 
compared with that of a range of human milk values and cow’s milk (Table 2-4). Values 19 
market in bold are higher than the range found in human milk and values market in italic are 20 
lower. In general, the content of 18:1n-9, LA and LNA were higher in the infant formulas 21 
than in human milk both in total fatty acids and in the sn2-position. The content of MCFA 22 
was more than 20 fold higher than in human milk in six of the formulas: two preterm, two  23 
for use in malabsorption, and two for use as energy supplement. DHA was detected in seven 24 
 7
out of the 28 formulas, and in the sn2-position of two, whereas ARA was detected in eight 1 
formulas and in the sn2-position of six. 2 
 The ratios of LA to LNA in all of the formulas and cow’s milk were within the 3 
interval recommended for standard infant formula of 5:1 to 15:1 (Tables 2-4), except 4 
Pregestimil, Super Soluble Duocal, Generaid Plus, Neocate and Therapeutic milk (all special 5 
formulas), which all had ratios >15:1. The proportions of LA in preterm infant formulas were 6 
about twice that in human milk, whereas that of LNA was similar to or twice that in human 7 
milk, resulting in LA-to-LNA-ratios that in most of the formulas were higher than in human 8 
milk.  9 
 10 
DISCUSSION 11 
Most infant formula fats are based on mixtures of vegetable oils or a blend of cow’s milk fat 12 
and vegetable oils that to some extent mimic the fatty acid profile of human milk, as observed 13 
in the present study. However, the stereospecific structure in the formulas differed 14 
considerably from that in human milk. Most (about 75 %) of the 16:0 in human milk was 15 
located in the sn2-position, whereas most of the 16:0 in the formulas was located in the outer 16 
positions of the triacylglycerols (75-97 %). Comparison of infant formulas and human milk 17 
showed that 18:1n-9 replaced 16:0 in the sn2-position, as in vegetable oils (e.g. rapeseed and 18 
palm oils). This indicates that the largest part of the fat used in the formulas was of vegetable 19 
origin, except for Baby Milk, which was primarily based on cow’s milk fat.  20 
 The human milk values we have used for comparison show a quite constant fatty acid 21 
pattern, despite the types of human milk being quite different (preterm milk, colostrums and 22 
mature milk). As expected the largest variation was in the content of DHA which is highly 23 
dependant on the mothers intake of DHA (19).  24 
 8
Constipation is more often observed in formula fed infants than in breast-fed infants 1 
(20). The structure differences between infant formula fats and human milk is one of the 2 
major reasons for the formation of insoluble calcium-soaps in the intestine. Betapol (Loders 3 
Croklaan, Wormerveer, The Netherlands) is a synthetic fat produced to mimic human milk 4 
fat both in total fatty acid profile and in structure (45 % of the 16:0 in the sn2-position). 5 
Studies with Betapol and other structured human milk substitutes showed that fats rich in 6 
sn2-16:0 compared to fats with a lower proportion of the 16:0 in the sn2-position improved 7 
absorption of 16:0 and calcium and reduced the excretion of calcium-soaps in the faeces of 8 
preterm infants (3), term infants (4) and rats (21). These studies support a beneficial 9 
physiological effect of the specific structured triacylglycerols on fat and calcium absorption. 10 
However, problems with calcium soap formation can also be solved by substituting 16:0 with 11 
other fatty acids, e.g. 18:1n-9, as in many of the infant formulas, or with medium chain fatty 12 
acids (MCFA.).    13 
High proportions of MCFA were found in special formulas for infants with 14 
malabsorption, lymphatic disorders, renal disease, liver disease (Pregestimil, Monogen, Super 15 
Soluble Duocal and Generaid Plus), and for preterm infants (PreNAN, Enfalac). These were 16 
added primarily instead of 16:0 as a readily available energy source. Infants with 17 
malabsorption can easier degrade, absorb and transport MCFAs than fatty acids of longer 18 
chain length. MCFAs are absorbed mainly to the portal vein and transported directly to the 19 
liver for β-oxidation (22). Formation of insoluble calcium-soaps in the intestine is low to 20 
non-existing, when MCFAs replace 16:0, due to the higher absorption (23,24). The 21 
nutritional value of special formulas with a high content of MCFA may be increased by 22 
addition of LCPUFA, possibly even further if the fat is structured (3). LCPUFA absorption 23 
has been shown to be improved in rats with malabsorption, if LCPUFA is supplied in fat with 24 
 9
MCFA in the outer positions and LCPUFA in the sn2-position (25,26) and so have fat 1 
utilisation and nitrogen retention in piglets (27).  2 
The LA and LNA content of infant formulas are believed to cover the need of n-6 and 3 
n-3 LCPUFA in term infants through elongation and desaturation to ARA and DHA. 4 
According to the current Nordic recommendations for infants 6-11 months of age the dietary 5 
intake of n-6 and n-3 PUFA should supply at least 4.0 % and 1.0 % of the energy intake, 6 
respectively (28). Since the fat content of breast-milk and formulas constitutes about 50 % of 7 
the energy, this is equivalent to a n-6 and n-3 PUFA content of approximately 8 and 2 wt%, 8 
respectively. Only four of the formulas in our study were found to have LNA content of 9 
around 2 wt%. The ESPGHAN Committee on Nutrition (29) and the Scientific Committee on 10 
Food (15) recommend that the ratio of LA to LNA in infant formulas should be 5-15. This 11 
recommendation was made in the absence of data on functional or clinical outcomes (30). 12 
Lowering the ratio of LA to LNA from 10:1 to 5:1 in formula fats resulted in modest increase 13 
in plasma DHA, but with no detectable effect on visual acuity or growth rate (30). Most of 14 
the formulas were found to have a high LA content well above that in human milk. A few of 15 
the formulas, mostly special formulas intended for infants with special needs, had a very high 16 
content of LA and ratios of LA to LNA between 17-55:1. Recent studies indicate that DHA 17 
formation is inhibited by a high supply of LA (31,32). Therefore, there may be a need to 18 
decrease the LA content, or supply LCPUFA, in order to meet the n-3 LCPUFA needs in 19 
infants. However, the ratio of LA to LNA in infant formulas has improved since we analysed 20 
infant formulas in the Danish market in the mid 1990s (33). 21 
Only seven of the 28 infant formulas contained DHA and only eight of them had 22 
ARA. In human milk 55 % of DHA was found to be specifically located in the sn2-position 23 
of the triacylglycerol. Of the seven infant formulas that contained DHA, only PreNAN and 24 
Enfalac had high levels in the sn2-position (34-50 %). Preterm infants have significantly 25 
 10
lower ARA and DHA status than full-term infants, because they do not receive the 1 
intrauterine supply of these fatty acids during late pregnancy (34). Dietary deficiency of ARA 2 
and DHA has therefore become an issue for the nutrition of preterm infants. Our results 3 
showed that the contents of these fatty acids in the formulas were similar to or lower than in 4 
human milk in four out of five formulas for ARA, and in all the preterm formulas for DHA. 5 
However, compared to other countries Danish mothers have a high n-3 LCPUFA intake and, 6 
thus, high levels of DHA in their milk (2).  7 
The ratio of LA to LNA and the presence of LCPUFA in some of the formulas 8 
demonstrate that an improvement of the fatty acid profiles of the infant formulas has taken 9 
place over the last decades, although the content of LNA is still low and that of LA high 10 
compared to current recommendations and compared to the content in human milk from 11 
Danish mothers. In the present study the structure analyses of the formulas showed that there 12 
was a discrepancy between the locations of the fatty acids in formula fats compared with that 13 
in human milk. In contrast to human milk, 16:0 in infant formulas was located primarily in 14 
the outer positions of the triacylglycerol molecules, which may increase the risk of 15 
constipation. Only few formulas contained LCPUFA, most of which was located in the outer 16 
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ARA  Arachidonic acid 7 
DHA  Docosahexaenoic acid 8 
FAME  Fatty acid methyl esters  9 
LA  Linoleic acid 10 
LCPUFA Long-chain polyunsaturated fatty acid 11 
LNA  α-linolenic acid 12 
MCFA  Medium-chain fatty acid  13 
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Table 2. The fatty acid profiles and composition in the sn2-position of triacylglycerols of human milk,  cow’s milk and infant formulas intended for preterm infantsa 
 






Innis et al (9) 
3 mo after elivery 
Jensen et al (6) 
Mature milk 
Martin et al (14)
Colostrum 
 Enfalac  Pre-Aptamil Pre-Babymin A   Pre-Babymin B Pre-NAN 
Triacylglycerol           
8:0b 0.2    1.1 22.3 2.3 0.7 2.0 15.8 
10:0 1.4  2.9 0.4 2.8 12.1 1.7 1.3 1.5 10.6 
12:0 5.7 4.1 7.3 4.8 3.4 1.6 13.5 5.2 11.4 0.5 
14:0 6.9 5.5 9.4 8.5 11.1 1.0 5.6 5.8 4.7 0.7 
16:0 25.7 21.0 27.0 25.8 32.3 6.1 15.9 28.6 17.1 11.2 
16:1 2.8 3.1 3.6 3.2 2.1 0.1 0.5 1.1 0.5 0.3 
18:0 8.1 7.1 7.1 5.9 11.2 2.5 4.4 6.8 4.5 3.0 
18:1t 0.7    2.9 - 0.2 0.3 0.1 - 
18:1n-9 33.1 40.2 34.2 32.6 20.7 29.0 40.4 33.4 37.3 35.9 
18:1n-7 1.8    0.6 0.7 1.0 0.9 1.0 1.0 
18:2 n-6 9.5 13.4 7.9 13.2 1.8 20.5 11.9 12.5 16.8 16.7 
18:3 n-3 1.1 1.5 trace 0.7 0.2 1.8 1.3 0.9 1.4 2.2 
20:4n-6 0.4 0.5  0.6 - 0.8 0.4 0.3 0.3 0.2 
22:6n-3 0.4 0.2  0.5 - 0.4 0.2 0.2 0.2 0.3 
others 2.3 1.2  3.5 9.8 1.2 0.6 2.1 1.2 1.4 
           
18:2n-6/18:3n-3 8.8 8.9  18.9 9.9 11.6 9.3 14.3 12.2 7.6 
           
sn-2 position           
8:0 0.2    0.8 21.3 0.2 0.1 0.1 13.6 
10:0 0.9  1.6 0.4 3.3 12.9 0.9 1.1 0.7 11.7 
12:0 6.1 2.5 6.9 3.8 4.9 2.7 24.0 6.4 19.7 0.8 
14:0 12.0 6.2 15.4 11.1 18.0 0.8 3.6 9.1 2.9 0.9 
Table
16:0 57.1 54.2 57.1 53.5 37.8 1.2 3.3 19.4 4.7 3.7 
16:1 2.9 3.5 1.6 3.2 2.6 0.1 0.3 1.1 0.3 0.3 
18:0 1.6 2.9 4.9 1.7 5.5 0.3 0.6 2.7 0.7 0.7 
18:1t -    2.3 - 0.1 0.2 0.1 - 
18:1n-9 9.5 17.1 8.1 13.8 15.3 31.8 45.5 39.1 44.0 41.2 
18:1n-7 0.7    0.4 0.3 0.5 0.6 0.6 0.2 
18:2n-6 5.4 8.1 3.7 8.4 1.8 25.5 18.7 17.7 24.3 23.0 
18:3n-3 0.5 0.9  0.4 0.4 1.5 2.1 0.8 1.6 3.1 
20:4n-6 0.3 0.7  0.7 - 0.7 0.1 0.1 0.1 - 
22:6n-3 0.6 0.4  0.7 - 0.6 - - - 0.3 
Others 1.7 0.9  3.4 6.9 0.3 0.2 1.5 0.3 0.4 
aData represent the average of two determinations for triacylglycerols and 3-4 determinations of the sn2-position and are expressed in wt% of total fatty acids in triacylglycerol or the sn2-position, respectively. 
bFatty acids are designated by the number of carbon atoms followed by the number of double bonds. The position of the first double bond relative to the methyl (n) end of the molecule is also indicated. 










Table 3. The fatty acid profiles and composition in the sn2-position in triacylglycerols of infant formula fata 
 
 Standard infant formula for term infants Follow-on formula (from 4 months) 
 Allomin Aptamil Baby Milk 
(liquid) 







Triacylglycerol             
8:0b 0.4 1.2 1.0 2.1 - 1.6 2.1 0.5 - 0.5 - 1.2 
10:0 0.9 1.4 1.7 1.7 0.1 1.1 1.2 1.0 - 1.1 0.1 0.9 
12:0 1.3 6.0 3.6 13.6 0.2 8.5 8.5 1.4 0.2 1.4 0.2 7.0 
14:0 4.4 5.8 7.0 5.7 0.9 3.9 4.0 4.7 0.7 4.7 0.9 3.3 
16:0 29.1 26.6 31.7 15.9 29.7 24.7 24.0 28.9 28.6 30.8 31.4 22.3 
16:1 0.7 1.1 1.1 0.5 0.2 0.2 0.2 0.7 0.2 0.8 0.2 0.2 
18:0 6.8 6.3 7.7 4.4 3.8 3.3 3.2 7.2 4.1 6.3 3.8 3.7 
18:1t 1.5 - 1.2 - - - - 1.6 - - - - 
18:1n-9 33.6 34.7 29.5 40.2 41.0 36.6 37.1 34.7 41.7 34.2 40.2 37.2 
18:1n-7 1.7 1.2 0.9 1.0 1.3 1.1 1.1 1.6 1.2 1.0 1.2 1.9 
18:2n-6 15.6 11.2 10.0 11.9 18.9 16.2 15.5 13.5 19.5 12.7 18.6 19.2 
18:3n-3 1.8 1.7 1.2 1.3 1.9 2.0 1.6 1.5 1.9 1.4 1.7 2.4 
20:4n-6 - 0.3 0.1 0.4 - - - - - - - - 
22:6n-3 - 0.2 - 0.2 - - - - - - - - 
others 2.3 2.2 3.3 1.1 2.1 0.8 1.5 2.7 1.9 5.1 1.8 0.8 
             
18:2n-6/18:3n-3 8.5 6.5 8.5 9.2 10.0 8.1 9.5 9.1 10.1 9.0 11.2 8.1 
             
sn2-position             
8:0 0.5 0.3 0.2 0.2 - 0.4 0.2 - - 0.1 - - 
10:0 0.7 0.9 1.6 0.8 - 0.5 0.6 0.5 - 0.6 - - 
Table
12:0 1.4 9.4 5.8 23.6 0.2 13.9 14.3 1.6 0.1 1.1 0.2 4.4 
14:0 6.9 7.2 11.2 3.6 0.7 2.1 2.4 7.1 0.6 3.9 0.7 1.7 
16:0 20.7 16.6 26.3 3.4 10.3 5.3 5.6 18.4 9.3 14.4 12.3 6.0 
16:1 0.8 1.1 1.4 0.3 0.1 0.1 0.1 0.9 - 0.5 0.1 - 
18:0 3.6 2.6 3.4 0.6 0.6 0.7 0.5 3.0 1.8 2.1 0.8 0.9 
18:1t 1.3 - 1.0 - - - - 1.3 - - - - 
18:1n-9 39.1 40.1 31.2 46.0 54.2 49.1 48.0 44.2 55.3 48.2 53.2 52.1 
18:1n-7 0.6 0.6 0.5 0.5 0.6 0.6 0.5 - 0.6 0.6 0.6 0.8 
18:2n-6 21.1 17.4 13.9 18.6 29.0 24.5 23.9 19.7 27.0 22.5 27.4 30.0 
18:3n-3 2.6 2.3 1.5 2.1 3.1 2.9 2.6 2.1 2.7 2.3 2.7 4.0 
20:4n-6 - 0.1 - 0.1 - - - - - - - - 
22:6n-3 - - - - - - - - - - - - 
Others 0.7 1.4 1.9 0.3 1.2 - 1.3 1.2 2.6 3.8 1.9 - 
 
aData represent the average of two determinations for triacylglycerols and 3-4 determinations of the sn2-position and are expressed in wt% of total fatty acids in triacylglycerol or the sn2-position, respectively. 
bFatty acids are designated by the number of carbon atoms followed by the number of double bonds. The position of the first double bond relative to the methyl (n) end of the molecule is also indicated. 
Values in bold are higher than the range of values for human milk (table 2) and values in italic are lower. 
 
 
Table 4. The fatty acid profiles and composition in the sn2-position of triacylglycerols of  foods for special medical purposea 
 























Triacylglycerol            
8:0b 23.5 51.5 1.2 2.2 1.4 1.5 35.4 - 1.4 23.3 3.9 
10:0 5.6 33.7 1.0 1.7 1.1 1.1 16.4 - 1.2 5.8 2.8 
12:0 13.6 0.5 7.8 13.0 9.1 8.8 0.1 0.3 9.5 13.8 22.2 
14:0 5.4 0.6 3.8 5.2 4.2 3.9 - 0.8 4.3 5.5 9.5 
16:0 8.3 2.7 24.3 8.3 22.6 22.9 4.4 27.7 22.2 7.9 25.6 
16:1 0.1 - 0.2 - 0.1 0.1 - 0.2 0.1 0.2 - 
18:0 2.7 2.0 4.0 4.1 3.7 3.8 1.4 3.3 4.1 2.4 8.4 
18:1t 0.3 - - - - - - 0.4 - - 1.3 
18:1n-9 13.7 2.6 35.8 46.6 37.9 36.5 20.3 48.2 36.2 13.8 20.0 
18:1n-7 0.3 - 1.8 0.6 1.4 0.8 0.4 2.2 0.8 0.3 - 
18:2n-6 25.2 5.3 17.1 16.3 17.1 18.3 20.1 14.5 17.7 26.0 5.2 
18:3n-3 0.7 1.0 2.0 1.0 1.2 1.4 1.0 1.7 1.8 0.5 0.3 
20:4n-6 - - - - - - - - - - - 
22:6n-3 - - - - - - - - - - - 
Others 0.4 - 1.0 0.9 0.1 1.0 0.5 0.7 0.7 0.6 0.7 
            
18:2n-6/18:3n-3 36.4 5.5 8.4 16.8 14.5 13.5 20.3 8.7 9.9 54.8 17.8 
            
sn2-position            
8:0 20.4 52.0 - 0.2 0.1 0.2 36.1 - 0.4 22.7 - 
10:0 5.6 39.0 - 0.9 0.4 0.4 19.6 - 0.6 5.9 1.0 
12:0 25.7 0.9 5.8 23.7 14.6 14.6 0.1 - 15.8 23.5 35.5 
14:0 3.3 1.1 1.8 3.2 2.4 2.4 - 0.2 2.1 2.9 5.1 
16:0 2.3 2.1 5.7 3.0 6.2 6.1 0.4 5.0 4.9 1.4 10.1 
16:1 0.1 - 0.2 - - - - 0.1 0.1 - - 
18:0 1.7 1.9 0.6 2.6 1.4 1.4 0.1 0.7 0.5 1.2 6.7 
18:1t 0.3 - - - - - - 0.6 - - 1.7 
18:1n-9 12.7 1.1 52.3 46.9 50.8 50.6 19.8 63.6 49.2 13.0 30.1 
18:1n-7 0.1 - 1.3 - 0.4 0.4 0.2 1.3 0.4 0.1 - 
18:2n-6 27.4 1.6 28.6 18.7 22.5 22.5 22.8 26.0 25.0 28.9 9.4 
18:3n-3 0.4 0.3 3.7 0.8 1.0 1.0 0.8 2.5 1.1 0.4 0.5 
20:4n-6 - - - - - - - - - - - 
22:6n-3 - - - - - - - - - - - 
Others - - 0.1 - - 0.3 0.1 - - - - 
 
aData represent the average of two determinations for triacylglycerols and 3-4 determinations of the sn2-position and are expressed in wt% of total fatty acids in triacylglycerol or the sn2-position, respectively. 
bFatty acids are designated by the number of carbon atoms followed by the number of double bonds. The position of the first double bond relative to the methyl (n) end of the molecule is also indicated. 
Values in bold are higher than for human milk and values in italic are lower. 
Table
Table 1. List of infant formulas and foods for special medical purpose, the year they were 
purchased, manufacturer and type and indications for special medical foods.   
 
Formula Purchased Manufacturer  
 
Formula for preterm infants 
 
Enfalac 2003 Mead Johnson  
Pre-Aptamil 2001 Milupa GmbH 
Pre-Babymin A 2000 Milupa GmbH 
Pre-Babymin B 2000 Milupa GmbH 
Pre-NAN 2000 Nestlé 
   
Infant formula for term infants 
 
 
Allomin 2003 Beauvais 
Allomin Soured 2003 Beauvais 
Aptamil 2001 Milupa GmbH 
Babymilk 2003 Arla 
Babymin 1999 Milupa GmbH 
HIPP 1 2002 HIPP GmbH & Co Vertrieb KG 
NAN 1 new 2003 Nestlé 
Nidina 1 2002 Nestlé 
   
Follow-on formula (from 4 months) 
 
 
Allomin 2 2003 Beauvais 
Allomin rice flour 2003 Beauvais 
HIPP 2 2002 HIPP GmbH & Co Vertrieb KG 
NAN 2 1999 Nestlé 
 
Foods for special medical purpose 
 
 
Generaid Plus 1999 SHS international (For hepatic disorders, for sole source of 
nutrition it is recommended to supplement with a source of α-
linolenic acid) 
Monogen 1999 SHS international (High content of MCT for use in lipid and 
lymphatic disorders) 
NAN H.A 2003 Nestlé (Hydrolyzed protein for infants at risk of allergy) 
Neocate 2003 SHS international (Protein as amino acids, for cow's milk allergy 
and multiple food intolerance) 
Nutramigen  2000 Mead Johnson (Hydrolyzed protein, for prevention and treatment 
of cow's milk allergy) 
Nutramigen 2  2003 Mead Johnson (Hydrolyzed protein, for prevention and treatment 
of cow's milk allergy from 4 months) 
Pregestimil 1999 Mead Johnson (Hydrolyzed protein for fat malabsorption) 
Profylac 1999 Alk (Hydrolyzed protein, for prevention and treatment of cow's 
milk allergy) 
Prosobee 2001 Mead Johnson (Soy-protein, for cow's milk allergy) 
Super Soluble Duocal 2001 SHS international (Energy supplement with carbohydrate and fat, 




Therapeutic milk   1999 Compact (For ”therapeutic feeding” in severely malnourished 
children in developing countries) 
   
 
Table
